Cargando…
Predictive biomarkers in precision medicine and drug development against lung cancer
The molecular characterization of various cancers has shown that cancers with the same origins, histopathologic diagnoses, and clinical stages can be highly heterogeneous in their genetic and epigenetic alterations that cause tumorigenesis. A number of cancer driver genes with functional abnormaliti...
Autores principales: | Fang, Bingliang, Mehran, Reza J, Heymach, John V, Swisher, Stephen G |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4593363/ https://www.ncbi.nlm.nih.gov/pubmed/26134262 http://dx.doi.org/10.1186/s40880-015-0028-4 |
Ejemplares similares
-
Introduction to this Special Issue: “Biomarker Discovery and Precision Medicine”
por: Fang, Bingliang
Publicado: (2020) -
Auranofin-mediated inhibition of PI3K/AKT/mTOR axis and anticancer activity in non-small cell lung cancer cells
por: Li, Hongyu, et al.
Publicado: (2015) -
Accumulation of RNA-dependent protein kinase (PKR) in the nuclei of lung cancer cells mediates radiation resistance
por: Hao, Chuncheng, et al.
Publicado: (2016) -
Major Pathologic Response and Prognostic Score Predict Survival in Patients With Lung Cancer Receiving Neoadjuvant Chemotherapy
por: Pataer, Apar, et al.
Publicado: (2022) -
Patient-derived tumor immune microenvironments in patient-derived xenografts of lung cancer
por: Pu, Xingxiang, et al.
Publicado: (2018)